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Luminal Narrowing After Percutaneous
Transluminal Coronary Angioplasty
A Study of Clinical, Procedural, and Lesional Factors
Related to Long-term Angiographic Outcome
Benno J. Rensing, MD; Walter R.M. Hermans, MD; Jeroen Vos, MD; Jan G.P. Tijssen, PhD;
Wolfgang Rutch, MD; Nicolas Danchin, MD; Guy R. Heyndrickx, MD; E. Gijs Mast, MD;
William Wijns, MD; Patrick W. Serruys, MD, on behalf of the Coronary Artery Restenosis
Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group
Background. The renarrowing process after successful percutaneous transluminal coronary angioplasty
(PTCA) is now believed to be caused by a response-to-injury vessel wall reaction. The magnitude of this
process can be assessed by the change in minimal lumen diameter (MLD) at follow-up angiography. The
aim of the present study was to find independent patient-related, lesion-related, and procedure-related
risk factors for this luminal narrowing process. A model that accurately predicts the amount of luminal
narrowing could be an aid in patient or lesion selection for the procedure, and it could improve assessment
of medium-term (6 months) prognosis. Modification or control of the identified risk factors could reduce
overall restenosis rates, and it could assist in the selection of patients at risk for a large loss in lumen
diameter. This population could then constitute the target population for pharmacological intervention
studies.
Methods and Results. Quantitative angiography was performed on 666 successfully dilated lesions at
angioplasty and at 6-month follow-up. Multivariate linear regression analysis was performed to obtain
variables with an independent contribution to the prediction of the absolute change in minimal lumen
diameter. Diabetes mellitus, duration of angina <2.3 months, gain in MLD at angioplasty, pre-PTCA
MLD, lesion length 26.8 mm, and thrombus after PTCA were independently predictive of change in MLD.
Overall prediction of the model was poor, however, percentage-correct classification for a predicted
change between -0.1 to -0.4 mm was approximately 10%. Lesions showing no change or regression
(change > -0.1 mm) and lesions showing large progression (<-0.4 mm) were more predictable (correct
classification, 59.5% and 49.7%, respectively).
Conclusions. Renarrowing after successful PTCA as determined with contrast angiography is a process
that cannot be accurately predicted by simple clinical, morphological, and lesion characteristics.
(Circulation. 1993;88:975-985.)
KEY WoRDs * angioplasty * restenosis * quantitative angiography
L uminal narrowing after percutaneous translumi-
nal coronary angioplasty (PTCA) is a complex
process that is only partially understood. Histo-
logical studies of coronary arteries after dilation, ob-
tained by either autopsy or atherectomy, have provided
evidence that strongly supports the concept of intimal
hyperplasia or proliferation of smooth muscle cells of
medial or intimal origin as the underlying cause of
luminal narrowing after angioplasty.1-3 Pharmacological
agents aimed at reducing the absolute amount of intimal
hyperplasia are currently being investigated in many
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clinical trials. In these trials, it is presumed that the
clinical outcome is related to an anatomic substrate, ie,
the prevention or reduction of reactive intimal hyper-
plasia after angioplasty.
If restenosis is viewed as an intraluminal growth
process after a successful angioplasty, risk factors for
restenosis should be risk factors for this growth process.
The angiographically determined change in lumen di-
ameter at follow-up is currently the only reliable indi-
cator of the amount of reactive hyperplasia applicable
to large study populations.
A model that accurately predicts the amount of
luminal narrowing in the individual patient would be of
value in several ways: First, it could be an aid in patient
or lesion selection for the procedure because an accu-
mulation of risk factors in the individual patient might
indicate balloon angioplasty as an unattractive means of
revascularization; second, it could improve assessment
of medium-term (6 months) prognosis in the individual
patient; third, modification or control of the identified
risk factors could reduce overall restenosis rates; fourth,
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FIG 1. Patient flow chart. CARPORT, Coronary Artery Re-
stenosis Prevention on Repeated Thromboxane Antagonism;
PTCA, percutaneous transumiinal coronary angioplasty; f-up,
follow-up; QCA, quantitative coronary angioplasty.
the model could assist in the selection of patients at risk
for a large loss in lumen diameter. This population
could then constitute the target population for pharma-
cological intervention studies because a larger mean
loss in lumen diameter would permit the enrollment of
a smaller number of patients in a study while maintain-
ing an equal power. Therefore, patient-related factors,
lesion-related factors, and procedural factors were cor-
related to the quantitative angiographic change in lu-
men diameter from postangioplasty angiogram to fol-
low-up angiogram in the present study.
Methods
Study Population
The study population consisted of 697 patients that
were originally randomized in six European centers (see
"Appendix") for the CARPORT Trial.4 In this random-
ized double-blind, placebo-controlled trial, a novel
thromboxane A2 receptor antagonist (GR32191B) was
investigated for its ability to prevent the restenosis
process after primary coronary angioplasty. Follow-up
on these patients was done on a prospective basis, and
all patients agreed to undergo repeat angiography at 6
months. Identical angiographic and clinical outcomes
were observed,4 so the placebo-treated and active treat-
ment group were pooled for the present study. All
patients with both stable and unstable angina and
angiographically proven native coronary artery disease
who were scheduled for primary angioplasty were con-
sidered for inclusion. Exclusion criteria for trial partic-
ipation and their relative frequencies have been pub-
lished earlier.4
Angioplasty success was defined as a <50% residual
stenosis by visual inspection of the postangioplasty
angiogram and no occurrence of in-hospital complica-
tions (death, acute myocardial infarction, repeat angio-
plasty, aortocoronary bypass grafting, or recurrence of
symptoms) and was achieved in 649 patients (93.1%).
Quantitative angiographic follow-up was available for
575 patients (88.6%), and this forms the study popula-
tion (Fig 1).
Angioplasty Procedure and Follow-up Angiography
Coronary angioplasty was performed with a steer-
able, movable guide wire system via the femoral route.
Standard available balloon catheters were used. Choice
of balloon type and brand as well as inflation duration
and inflation pressure were left to the discretion of the
angioplasty operator. At the beginning of the angio-
plasty procedure, all patients received 10000 IU of
intravenous heparin for the first 2 hours and afterward,
5000 lU/h for as long as the procedure continued. All
patients received 10 mg nifedipine every 2 hours for the
first 12 hours after angioplasty. Thereafter, they re-
ceived 20 mg slow-release nifedipine tablets three times
during the second day after angioplasty.
Three coronary angiograms were obtained in each
patient just before angioplasty, immediately after angio-
plasty, and at follow-up. To standardize the method of
data acquisition and to ensure exact reproducibility of
the angiographic studies, measurements were taken as
described previously.5-7 The angiograms were recorded
in such a way that they were suited for quantitative
analysis by the Coronary Angiography Analysis System
(CAAS). All necessary details of the procedure were
recorded, and drawings of the segments to be analyzed
were made. For calibration purposes, the catheter tips
were cut off for later measurement with a microcaliper.
All angiograms were processed and analyzed in a cen-
tral core laboratory. At least two views of all lesions
were analyzed-orthogonal if possible. A difference in
angulation of at least 300 was required for a view to be
separately analyzed.
The follow-up coronary angiogram was performed at
6 months. If symptoms recurred within 6 months, coro-
nary angiography was carried out earlier. If no definite
restenosis was present and no revascularization proce-
dure was performed and the follow-up time was less
than 4 months, the patient was asked to undergo
another coronary arteriogram at 6 months.
Quantitative Angiography
All cineangiograms were analyzed using the comput-
er-assisted angiography analysis system (CAAS), which
has been described and validated previously.8,9 A com-
puter-derived reconstruction of the original arterial
dimension at the site of obstruction (assuming there is
no disease present) is used to define the interpolated
reference diameter. The area between the actual and
reconstructed contours at the obstruction site is a
measurement for the amount of atherosclerotic plaque
and is expressed in millimeters squared. The length of
the obstruction is determined from the diameter func-
tion on the basis of curvature analysis and is expressed
in millimeters. In addition, this technique allows for the
calculation of an eccentricity index of the lesion.10 The
index ranges from 0 (severe eccentric) to 1 (perfectly
symmetrical). Since the analysis system cannot measure
total occlusions, a value of 0 mm was substituted for the
minimal lumen diameter, and the postangioplasty ref-
erence diameter was substituted for the reference di-
ameter before PTCA. The mean change in minimal
lumen diameter from postangioplasty angiography to
follow-up angiography and from before angioplasty to
after angioplasty was derived from matched angio-
graphic views.
Potential Risk Factors Studied
The loss in minimal lumen diameter was assessed for
factors reported to be predictive of luminal narrowing
after successful PTCA. For categorical variables, the
change in lumen diameter from postangioplasty angio-
697 patients enrolled in CARPORT trial
H 48 failed PTCA (6.9%)
649 patients eligible for f-up angiography
* 46 refused re-anglography
18 contraindicatIon for re-anglography
~ 2 died
0 8 f-up angiograms unsuitable for OCA
575 patients with analyzable f-up angio(88.6%)
 at SWETS SUBS SERVICE on January 11, 2010 circ.ahajournals.orgDownloaded from 
Rensing et al Factors Related to Luminal Narrowing After PTCA 977
gram to follow-up angiogram was determined in each
category. Continuous variables were grouped into three
equally sized subgroups (tertiles), and the change in
minimal lumen diameter was assessed for each tertile.
Variables potentially predictive for luminal narrowing
and eventually restenosis were divided into three gen-
eral categories. (1) Patient-related factors are present
systemically and thereby affect all dilated lesions in a
single patient. These include age, sex, diabetes, unstable
angina (defined as pain at rest requiring treatment with
intravenous nitrates), extent of atherosclerotic disease
(single or multivessel), previous myocardial infarction,
previous CABG, previous angioplasty at another site,
platelet count, cholesterol level, lipoprotein cholesterol
levels (high-density and low-density lipoproteins), glu-
cose levels, history of smoking, and continued smoking
after the procedure. Because only eight patients had
type I diabetes, diabetes type I and II were pooled. (2)
Lesion-related factors are characteristics unique to each
lesion. The following factors were assessed: minimal
lumen diameter before and after PTCA, lesion length,
eccentricity of the lesion, percentage diameter stenosis
before and after PTCA, presence of visible collateral
circulation to the dilated vessel, total occlusion before
PTCA, plaque area before PTCA, vessel dilated (either
left anterior descending artery, circumflex artery, or
right coronary artery), presence of dissection after
angioplasty (defined as filling defect within the lumen
disappearing with the passage of contrast material [type
A dissection, according to Dorros et all']), and as
contrast appearing outside the lumen, disappearing or
persisting with the passage of contrast material (type B
and C dissections, according to Dorros et al), relative
gain in lumen diameter achieved by angioplasty (de-
fined as the difference in obstruction diameter before
and after angioplasty divided by the interpolated refer-
ence diameter [vessel size]), presence of thrombus
before and after PTCA (defined as an intraluminal
filling defect visible in all views, a visible embolization of
intraluminal material downstream, or dye staining at the
site of a total occlusion [interobserver concordance rate
for the assessment of intracoronary thrombus in the
core lab 89%]), and calcification of the lesion. (3)
Procedure-related factors assessed were maximal mea-
sured balloon diameter, balloon-artery ratio (defined as
the ratio of the quantitative angiographic diameter of
the largest balloon at highest inflation pressure to the
reference diameter), maximal inflation pressure, num-
ber of balloon inflations, and total duration of balloon
inflation.
Data Analysis
The unit of analysis reported here is the stenotic
lesion, not the patient. The primary outcome variable
was the change in lumen diameter from directly after
angioplasty to follow-up angiogram. For the univariate
analysis, continuous variables were divided into tertiles,
and the three subgroups were compared with respect to
absolute lumen change using an ANOVA. For the
subgroups defined by binary variables, lumen change
was compared using a Student's t test.
To obtain independent predictors for the loss in
lumen diameter, variables were entered in a stepwise
multiple linear regression analysis in which the loss in
lumen diameter was the dependent variable. Stepwise
multiple linear regression analysis was performed (BMDP
statistical package, program 2R) to assess the relation
between the variables mentioned in "Methods" (inde-
pendent variables=Xi) and the loss in minimal lumen
diameter from postangioplasty angiogram to follow-up
angiogram (dependent variable=Y): Y=A+YiBiXi,
where A is the intercept and Bi is the ith regression
coefficient. The standard BMDP 2R criteria of F >4 for
inclusion and F <3.9 for elimination were applied.
Continuous variables were entered as such in the
multivariate analysis except for variables with two of
three tertiles showing approximately the same amount
of loss in lumen diameter for each tertile. These were
entered as discrete variables (lesion length .6.8 mm,
cholesterol level .6.5 mmol/L, duration of angina <2.3
months, and percent diameter stenosis before angio-
plasty .56.5%).
A second multiple linear regression analysis on a
per-patient basis was done to confirm the per-lesion
results, which might be biased because of lack of
independence among multiple dilated lesions in the
same patients. In this analysis, only the lesion that
narrowed the most was taken into consideration.
To determine how well the regression model per-
forms in predicting the magnitude of the restenosis
process according to two frequently applied restenosis
criteria and to illustrate the discrepancies between the
two criteria, receiver operator characteristic (ROC)
curves were constructed for each criterion. The criteria
applied were: change in lumen diameter .0.72 mm at
follow-up-5812 and the classic criterion of an increase in
diameter stenosis from <50% before PTCA to .50% at
follow-up. The 0.72-mm value takes into account the
limitations of coronary angiographic measurements and
represents twice the long-term variability for repeat
measurements of a coronary obstruction using the
CAAS system.8 The use of 1 SD would include 68.3% of
the measurement variability, whereas the use of 2 SD
(2x0.36=0.72 mm) includes 95.5% of the measurement
variability. The equivalent of the 0.72-mm value for
diameter stenosis measurements is a change in diameter
stenosis of 13%. In these ROC curves, sensitivity (true
positive %) at different cut-off points of predicted
change in minimal lumen diameter is graphed as a
function of 100% minus specificity (false-positive %).
Results
Of 649 patients who had a successful angioplasty, 575
underwent satisfactory angiographic follow-up (fol-
low-up rate, 88.6%) and formed the study population.
Baseline characteristics of the study population are
summarized in Table 1. A total of 666 lesions were
successfully dilated. Restenosis rate was 32.6% (217 of
666 lesions) according to the >50% diameter stenosis
criterion and 17.6% (117 of 666 lesions) if the criterion
of >0.72-mm loss in lumen diameter was applied.
Univariate Analysis
Patient-related variables. Table 2 summarizes the
changes in minimal lumen diameter for all analyzed
patient-related variables. Of the 18 patient-related vari-
ables, only three (unstable angina, diabetes, and angina
duration <2.3 months) showed a significantly larger loss
in minimal lumen diameter at follow-up. The high loss
in lumen diameter associated with the presence of these
variables was probably caused by lesions that progressed
toward total occlusion at follow-up. Indeed, if totally
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TABLE 1. Baseline Characteristics of Study Patients
No. of patients
Lesions
Lesions per patient
Age (y)
Male sex (%)
Follow-up time (d)
Extent of disease
1 Vessel
2 Vessels
3 Vessels
No. of lesions dilated
1
2
3
MLD before PTCA (mm)
MLD after PTCA (mm)
MLD at follow-up (mm)
%DS before PTCA
%DS after PTCA
%DS at follow-up
Change in MLD at follow-up (mm)
575
666
1.16
56±9 (29-79)
464 (81%)
172±42 (10-349)
381 (66.3%)
156 (27.1%)
38 (6.6%)
485
74
11
1.04±0.37 (0.00-2.83)
1.76±0.38 (0.85-3.04)
1.48±0.59 (0.00-3.15)
60±13 (18-100)
34±9 (6-76)
45±19 (4-100)
-0.28±0.50
MLD, minimal lumen diameter; PTCA, percutaneous translu-
minal coronary angioplasty; %DS, percentage diameter stenosis.
occluded lesions at follow-up (n=42, 6.3%) were ex-
cluded from the analysis, then a trend toward a higher
loss in lumen diameter in the presence of one of these
factors still existed, although not statistically significant:
diabetes: -0.27±0.39 versus -0.20±0.39 mm, P=.18;
unstable angina: -0.20±0.39 mm versus -0.18±0.39
mm, P=.66; duration of angina <2.3 months,
-0.24±0.37 mm versus -0.18±0.40 mm, P=.09.
Lesion-related variables. The preangioplasty lesion-
related factors associated with a larger loss at follow-up
were smaller minimal lumen diameter, lesion length
.6.8 mm, higher percentage diameter stenosis, larger
plaque area, total occlusion, and collateral circulation to
the obstruction site (Table 3). The postangioplasty
lesion-related factors associated with a greater loss at
follow-up were a larger postangioplasty lumen diame-
ter, lower percentage diameter stenosis after angio-
plasty (ie, a better angioplasty result), a higher relative
gain achieved at angioplasty, and thrombus after angio-
plasty. Again, if total occlusions at follow-up were
disregarded, the presence of total occlusions before
angioplasty, collateral circulation, and thrombus after
angioplasty were no longer associated with a signifi-
cantly higher loss in minimal lumen diameter (total
occlusion, -0.11±0.42 mm versus -0.20±0.39 mm,
P=.25; collateral circulation, -0.23+±0.41 mm versus
-0.19±0.39 mm, P=.34; thrombus after angioplasty,
-0.25+±0.39 mm versus -0.20±0.39 mm, P=.67).
Procedure-related variables. None of the procedural
factors assessed was associated with a significantly
greater loss in lumen diameter at follow-up (Table 4).
Multiple Linear Regression Analysis
The stepwise multiple linear regression analysis
showed two preangioplasty angiographic characteristics
as predictive of luminal narrowing at follow-up, namely,
length of the stenosis and the minimal lumen diameter
TABLE 2. Change in Minimal Lumen Diameter per Lesion for
Patient-Related Variables
Change in MLD
at follow-up (mm) P
Age (y)
<52 (n=211)
52-61 (n=213)
>61 (n=242)
Sex
Male (n=533)
Female (n= 133)
Diabetes I and II
Yes (n=56)
No (n=610)
Unstable angina (pain at rest)
Yes (n=91)
No (n=575)
Extent disease
Single vessel (n=401)
Multivessel (n=265)
Ever smoked
Yes (n=515)
No (n=151)
Still smoking at follow-up
Yes (n=81)
No (n=585)
Previous MI
Yes (n=253)
No (n=413)
Previous CABG
Yes (n=20)
No (n=646)
Previous PTCA another site
Yes (n=11)
No (n=655)
Duration of angina (mo)
<2.3 (n=210)
2.3-8.5 (n=227)
>8.5 (n=229)
Platelet count (106/mL)
<168 (n=216)
168-175 (n=220)
.175 (n=222)
Total cholesterol (mmol/L)
<5.7 (n=225)
5.7-6.5 (n=217)
>6.5 (n=216)
HDL cholesterol (mmol/L)
<0.93 (n=190)
0.93-1.2 (n=197)
>1.20 (n=188)
LDL cholesterol (mmol/L)
<3.3 (n=166)
3.3-4.6 (n= 169)
.4.6 (n=157)
Glucose (mmol/L)
<4.8 (n=234)
4.8-5.6 (n=213)
.5.6 (n=210)
Hypertension
Yes (n=223)
No (n=443)
AP class at baseline*
III (n=290)
III,IV (n=376)
-0.26±0.51
-0.31±0.52
-0.31±0.57
-0.28±0.50
-0.37±0.65
-0.56±0.77
-0.27±0.50
-0.42±0.73
-0.27±0.50
-0.31±0.55
-0.28±0.52
-0.28±0.54
-0.34±0.53
-0.23±0.46
-0.34±0.53
-0.33±0.60
-0.27±0.50
-0.22±0.42
-0.30±0.54
.54
.11
<.001
<.05
.45
.28
.22
.13
.45
.77
.06
.48
.15
.50
.11
.18
.51
-0.25±0.57
-0.29±0.54
-0.37±0.59
-0.26±0.50
-0.26±0.53
-0.30±0.56
-0.27±0.50
-0.33±0.55
-0.32±0.56
-0.34±0.58
-0.26±0.47
-0.32±0.58
-0.26±0.49
-0.31±0.54
-0.36±0.59
-0.31±0.52
-0.24±0.47
-0.26±0.47
-0.30±0.54
-0.35±+0.61
-0.31±0.54
-0.28±0.54
-0.27±0.49
-0.32+0.59
.25
MLD, minimal lumen diameter; MI, myocardial infarction;
CABG, coronary artery bypass grafting; PTCA, percutaneous
transluminal coronary angioplasty; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; AP, angina pectoris.
*Canadian Cardiovascular Society classification.
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TABLE 3. Change in Minimal Lumen Diameter per Lesion at
Follow-up for Lesion-Related Variables
Change in MLD
at follow-up (mm) P
MLD before PTCA (mm)
<0.9 (n=219)
0.9-1.15 (n=216)
21.15 (n=228)
MLD after PTCA (mm)
<1.65 (n=220)
1.65-1.9 (n=221)
21.90 (n=225)
Relative gain at PTCA
<0.2 (n=230)
0.2-0.3 (n=209)
20.3 (n=224)
Length obstruction (mm)
<5.25 (n=229)
5.25-6.8 (n= 195)
.6.8 (n=203)
Plaque area (mm2)
<4.7 (n=208)
4.7-7.6 (n=212)
.7.6 (n=207)
Eccentricity
<0.2 (n=210)
0.2-0.45 (n=205)
.0.45 (n=212)
% Diameter stenosis before PTCA
<56.5 (n=244)
56.5-64.5 (n=210)
264.5 (n=209)
% Diameter stenosis after PTCA
<29.5 (n=217)
29.5-38 (n=225)
.38 (n=224)
Vessel size (mm) (reference diameter)
<2.4 (n=240)
2.4-2.85 (n=214)
.2.85 (n=212)
Patency before PTCA
Total occlusion (n=36)
Patent (n=630)
Collateral circulation to obstruction site
Yes (n=122)
No (n=544)
Thrombus before PTCA
Yes (n=32)
No (n=634)
Thrombus after PTCA
Yes (n=16)
No (n=650)
Vessel dilated
LAD (n=321)
LCx (n=154)
RCA (n= 191)
Calcified lesion
Yes (n=233)
No (n=433)
Tandem lesion
Yes (n=25)
No (n=641)
Dissection after PTCA
Yes (n=125)
No (n=541)
Branch in stenosis
Yes (n=194)
No (n=472)
-0.37±0.58
-0.31±0.51
-0.22±0.51
-0.16±0.48
-0.33±0.50
-0.39±0.55
-0.13±0.45
-0.33±0.49
-0.46±0.58
-0.23±0.46
-0.24±0.51
-0.38±0.55
-0.21±0.45
-0.29±0.53
-0.34±0.53
-0.31±0.52
-0.26±0.50
-0.27±0.50
-0.20±0.48
-0.35±0.54
-0.35±0.58
-0.40±0.57
-0.32±0.53
-0.17±0.49
-0.30±0.53
-0.30±0.51
-0.28±0.57
-0.54±0.87
-0.28±0.50
-0.39±0.64
-0.25±0.49
-0.32±0.51
-0.29±0.52
-0.71±0.90
-0.28±0.52
-0.27±0.46
-0.28±0.55
-0.34±0.63
-0.29±0.50
-0.31 ±0.56
-0.27±0.39
-0.29±0.54
-0.32±0.59
-0.29±0.52
-0.31±0.49
-0.29±0.56
<.02
<.001
<.001
<.01
<.03
.42
<.001
TABLE 4. Change in Minimal Lumen Diameter per Lesion at
Follow-up for Procedure-Related Variables
Change in MLD
at follow-up (mm) P
Maximal balloon diameter (mm)
<2.35 (n=189) -0.26±0.50
2.35-2.7 (n=214) -0.30±0.50 .11
.2.7 (n=192) -0.35±0.55
Balloon-artery ratio
<0.9 (n=201) -0.27±0.55
0.9-1.05 (n=201) -0.29±0.53 .17
>1.05 (n=193) -0.36±0.54
No. of inflations
1 (n=178) -0.29±0.47
2-4 (n=254) -0.30±0.51 .55
>4 (n=234) -0.35+0.57
Maximal inflation pressure (atm)
<8 (n=261) -0.31±0.58
8-10 (n=264) -0.30±0.52 .43
210 (n=141) -0.24±0.50
Total inflation duration (s)
<220 (n=202) -0.30±0.54
220-470 (n=230) -0.28±0.52 .69
>470 (n=224) -0.27±0.48
MLD, minimal lumen diameter.
before angioplasty (Table 5). Only two clinical variables
and two postangioplasty variables, namely, diabetes,
<.001 duration of angina, the relative gain in lumen diameter
achieved at angioplasty, and thrombus after angioplasty
were found to be independently predictive for luminal
narrowing after balloon angioplasty.
.91 To rule out any influence of the investigational drug
on our findings, the use of either the thromboxane A2
<.01 receptor blocker GR32191 or placebo was forced into
the model. Trial medication had only a very small,
statistically insignificant contribution to the fit of the
<.05 model (Table 5).
In an attempt to assess how well the model predicted
the amount of luminal narrowing at follow-up, the
.65 percentage of correct classified lesions was calculated
for five intervals of predicted change in lumen diameter
(Table 7). Correct prediction by the model was poor,
<.01 particularly in the range of predicted change from -0.1
.36
.61
.82
.60
.69
TABLE 5. Multivariate Linear Regression Model for the
Prediction of Change in Lumen Diameter
SE of F to
Model Coefficient coefficient remove
Intercept 0.40
Relative gain at PTCA -1.36 0.18 57.5
MLD before PTCA -0.19 0.07 6.7
Lesion length >6.8 mm -0.19 0.04 19.7
Diabetes -0.34 0.07 20.7
Duration of angina
<2.3 months -0.11 0.04 6.2
Thrombus after angioplasty -0.31 0.14 5.2
Allocation to GR32191B 0.03 0.04 0.5
Per-lesion analysis (n=666).
SE, standard error; PTCA, percutaneous transluminal coronary
angioplasty; MLD, minimal lumen diameter.
MLD, minimal lumen diameter; PTCA, percutaneous translu-
minal coronary angioplasty; LAD, left anterior descending artery;
LCx, left circumflex artery; RCA, right coronary artery.
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TABLE 6. Multivariate Linear Regression Model for the
Prediction of Change in Lumen Diameter
SE of F to
Model Coefficient coefficient remove
Intercept 0.43
Relative gain at PTCA -1.42 0.20 51.0
MLD before PTCA -0.22 0.08 7.2
Lesion length >6.8 mm -0.19 0.04 16.9
Diabetes -0.32 0.08 14.9
Duration of angina
<2.3 months -0.11 0.05 5.6
Thrombus after angioplasty -0.31 0.14 5.2
Allocation to GR32191B 0.01 0.04 0.06
Per-patient analysis. For multilesion, only the most narrowed
lesion was taken into account (n=575).
SE, standard error; PTCA, percutaneous transluminal coronary
angioplasty; MLD, minimal lumen diameter.
to -0.4 mm. In fact, only 10% of lesions in the middle
three categories were correctly classified by the model.
On the other hand, lesions showing no change or
regression and lesions showing large progression were
more predictable. The information content of the model
according to the ROC curves (Fig 2) was optimal for the
"loss of .0.72 mm" restenosis criterion. For the ">50%
diameter stenosis" criterion, the curve was very close to
the line of "no prognostic value." If, in addition to
>50% diameter stenosis at follow-up, a loss of at least
13% in percent diameter stenosis (twice the long-term
variability for diameter stenosis measurements, using
our analysis system) was required for a lesion to be
classified as restenosis, a shift of the ROC curve to the
left upper corner was apparent. These findings under-
0 20 40 60 80 100
False positives (%)
FIG 2. Receiver operator characteristic (ROC) curves for
comparison of restenosis criteria at different cut-offpoints of
predicted change in lumen diameter. The diagonal line is the
line of identity or line of "no prognostic value. " ROC curves
on the line of identity have no prognostic value; those in the
left upper corner are most informative. Solid curve: 0. 72 mm
criterion (area under curve, 69.6%); normal curve: 50%
diameter stenosis criterion with a change in diameter stenosis
at follow-up of at least 13% (area under the curve, 62.2%);
dotted curve: 50% diameter stenosis criterion (area under
curve, 54.8%).
TABLE 7. Percentages of Correct Classification
Interval of predicted Percentage correct
change in MLD classification*
-0.4 mm 98/197 (49.7%)
-0.3 to -0.4 mm 9/116 (7.8%)
-0.2 to -0.3 mm 13/123 (10.5%)
-0.1 to -0.2 mm 12/106 (11.3%)
>-0.1 mm 72/121 (59.5%)
MLD, minimal lumen diameter.
*Total amount of lesions is 663 because gain could not be
calculated for three lesions that were located distal to a total
occlusion before percutaneous transluminal coronary angioplasty;
therefore, the minimal lumen diameter is unknown.
score the poor predictability of luminal narrowing and
restenosis after balloon angioplasty and explain the
differences between the restenosis criteria.
In an attempt to do an analysis on a per-patient
rather than on a per-lesion basis, the analysis was
repeated. In case of multilesion dilatations, only the
lesion that narrowed the most was considered for this
analysis. In Table 6, the results of this analysis are
summarized. The same variables were retained with
almost equal coefficients. Only a visible thrombus on the
postangioplasty angiogram was not retained in the
multiple linear regression analysis on a per-patient basis
(F to enter was 3.6).
Discussion
During 15 years of percutaneous transluminal coro-
nary balloon angioplasty, an abundance of clinical and
experimental studies have been carried out in an at-
tempt to elucidate factors that can predict the "Achilles'
heel" of coronary angioplasty, namely progressive lumi-
nal narrowing after a successful procedure. Although
many clinical, procedural, and lesion-related factors
have been linked with a higher angiographic restenosis
rate, results of these studies are sometimes conflicting.
As pointed out by Beatt et al,13 most of the discrepan-
cies can be attributed to (1) patient selection, (2) the
method of analysis, and (3) the definition of angio-
graphic restenosis used.
Patient Selection
To obtain objective, unbiased results, all patients
should be recatheterized after a predetermined fol-
low-up period regardless of their symptomatic status.
Failure to perform angiographic follow-up in a majority
of patients will introduce bias in the assessment of the
true change in minimal lumen diameter at follow-up.
The restenosis rate according to a more or less arbitrary
cut-off point will be biased toward higher values if
symptomatic patients or patients with unfavorable anat-
omy after angioplasty are preferentially recatheterized.
In this study, 88.6% of all patients with a successful
angioplasty had a follow-up angiogram performed
within a predetermined time frame of 6 months.
Method ofAnalysis
A well-validated quantitative angiographic analysis
system should be used. Computer-assisted automated
edge detection techniques enhance objectivity and re-
producibility and reduce the high interobserver and
intraobserver variability inherent to visual interpreta-
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tion of the coronary angiogram.1415 The quantitative
analysis system we applied for the analysis of the
angiograms meets these requirements.13 Recently we
performed a study16 comparing luminal dimensions 24
hours after angioplasty with those on the immediate
postangioplasty angiogram using the same methodology
as in the present study. Mean difference in minimal
lumen diameter (accuracy) of 119 lesions was 0.00 mm,
with a standard deviation (precision) of 0.20 mm. It was
concluded that (1) in the first 24 hours after angioplasty,
no major renarrowing takes place, and (2) variability of
the CAAS measurements immediately after balloon
dilatation is less than the long-term variability of the
method.8 It should be noted that this long-term variabil-
ity was measured 8 years ago on stenoses not submitted
to angioplasty and with a reference diameter of 3.6 mm
(present study, 2.6 mm). Also, standardization of angio-
film recording was not performed in the CAAS variabil-
ity study.8 In that study, no attempt was made to
standardize on technical characteristics of the x-ray
gantry or on vasomotor tone (intracoronary injection of
the same amount of nitrates before pre-PTCA, post-
PTCA and follow-up angiography). We therefore feel
that the long-term variability of the system under a
strictly standardized angiography protocol is closer to
0.20 mm than the earlier reported 0.36 mm. However,
even if a precision of 0.20 mm is regarded as correct in
the setting of this study, part of the changes in lumen
diameter fall within the measurement error of tech-
nique. This can be a possible reason for the poor fit of
the multiple linear regression equation. Another point
of concern with quantitative analysis of a lesion imme-
diately after angioplasty is the amount of analyst inter-
ference with the automated edge detection technique.
In our population, the amount of editing performed by
the analysts was 3.7% before angioplasty, 4.2% after
angioplasty, and 3.7% at follow-up angiography; that is,
4.2% of the automatically detected vessel contours were
corrected by the analysts. The interobserver and intra-
observer variability of the analysis of the postangio-
plasty angiogram is subject to ongoing investigation, and
data are not yet available. We can therefore conclude
that for quantitative analysis of the immediate postan-
gioplasty angiogram, most likely the same variability
values apply as for quantitative analysis of nondilated
vessel segments.
Restenosis Criteria
The third factor influencing the restenosis rates is the
restenosis criterion. The most frequently applied crite-
rion in the literature is the >50% diameter stenosis at
follow-up criterion. This criterion is historically based
on the physiological concept of coronary flow reserve
introduced by Gould and others17 in 1974 and is taken
because it represents the approximate value in animals
with normal coronary arteries at which blunting of the
hyperemic response occurs. Although this criterion may
be of some relevance in determining a clinically signif-
icant stenosis in human atherosclerotic vessels, it is a
static measurement of lesion severity and tells us noth-
ing about the dynamic behavior of the restenosis pro-
cess. If the "50% diameter stenosis at follow-up" crite-
rion is applied, lesions with a suboptimal angioplasty
result will preferentially be selected (ie, will have to
undergo a small loss in lumen diameter to be classified
as restenosed). Bourassa et al18 have recognized this
shortcoming and thus considered lesions with .50%
diameter stenosis at follow-up that did not show a
change of at least 10% at follow-up as not "restenosed."
The predictive accuracy of the multivariate model for
restenosis according to the 50% diameter stenosis cri-
terion was very poor (Fig 2). If in addition a change in
percent diameter stenosis of at least 13% (twice the
long-term variability for percent diameter stenosis mea-
surements) was required, then predictive accuracy of
the model improved markedly, since lesions with a
suboptimal angioplasty result no longer unduly influ-
enced the restenosis rate. This requirement shifts the
ROC curve to the left upper corner. A criterion that
better reflects the dynamic behavior of the lesion after
PTCA is the .0.72-mm loss in lumen diameter criterion
as proposed by our group.5'8"2 This criterion is not
meant to be a restenosis criterion strictu sensu, since
that also implies some sort of functional measure of
lesion severity at follow-up, but rather an indicator of
significant intraluminal growth as monitored
angiographically.
Predictive Factors for Luminal Narrowing After
Balloon Angioplasty
If restenosis is viewed as an intraluminal growth
process after a successful angioplasty, risk factors for
restenosis should be risk factors for this growth process.
Therefore, we determined risk factors for the absolute
amount of quantitative angiographic luminal narrowing
rather than for the crossing of a more or less arbitrary
cut-off point (eg, 50% diameter stenosis or loss .0.72
mm).
A distinction should be made between lesions that
progress toward total occlusion and lesions that remain
patent at follow-up, since it is likely that part of the
luminal narrowing observed in former lesions is caused
by thrombosis and not only by the fibroproliferative
process. The larger luminal narrowing in lesions in
patients with diabetes, unstable angina, in totally oc-
cluded lesions, lesions with visible collateral circulation,
and lesions with a visible thrombus after angioplasty
was largely determined by a higher incidence of total
occlusions at follow-up.
Patient-Related Factors
Diabetes, unstable angina, and duration of angina
shorter than 2.3 months were associated with more
luminal narrowing at follow-up. If total occlusions at
follow-up were disregarded, none of these variables
showed significantly more narrowing. In multivariate
analysis however, diabetes was independently predictive
of luminal narrowing.
The assumption that risk factors for the magnitude of
the restenosis process are similar to risk factors for
atherosclerosis was not confirmed in the present study.
Only diabetes was found to be independently related to
the amount of luminal narrowing at follow-up. This
finding has also been recognized by others.19-26 In a
recent study by Bourassa et al18 using the same quanti-
tative angiographic analysis system, diabetes was not
found to be predictive of restenosis. Other classic risk
factors for atherosclerosis such as male sex, systemic
hypertension, high cholesterol level, and continued
smoking after the PTCA were not found to be related to
luminal narrowing in the present study. The controversy
regarding these risk factors is considerable, with many
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studies being positive for one or more patient-related
factors and many studies being negative.2728
Lesion-Related Factors
Preangioplasty variables. In univariate analysis, five
preangioplasty variables were associated with more
luminal narrowing at follow-up: minimal lumen diame-
ter before angioplasty, percent diameter stenosis before
angioplasty, length of stenosis, total occlusion before
angioplasty, and collateral circulation to dilatation site.
A relation between stenosis severity and restenosis rate
has been shown previously.18'20'21'29 It is conceivable that
more severe lesions undergo more severe vessel wall
damage during the procedure, a known trigger for the
hyperplastic reaction.30-32 In our multivariate analysis,
the preangioplasty minimal lumen diameter was found
to be an independent determinant of subsequent loss in
lumen diameter. In longer lesions, more smooth muscle
is possibly exposed to injury and platelet adhesion,
which probably enhances the intimal hyperplastic
reaction.
A relation between stenosis length and the restenosis
process has also been described by others.18'3334 Total
occlusion before angioplasty is a well-known factor
connected with total occlusion at follow-up35'36 and thus
a large loss in lumen diameter at follow-up. Because
total occlusion before angioplasty is part of the contin-
uous-variables minimal lumen diameter and diameter
stenosis before PTCA, total occlusion before angio-
plasty was not found to be an independent predictor of
loss in lumen diameter.
Collateral circulation to the dilatation site will be
more abundant in case of a severe stenosis or total
occlusion. Since the severity of the lesion (minimal
lumen diameter) before angioplasty was found to be an
independent determinant for the absolute loss in lumen
diameter at follow-up, the presence of collaterals was
not retained in the model.
No differences in luminal narrowing was observed for
the three coronary arteries. Others23,2837-39 have re-
ported a higher incidence of restenosis for the left
anterior descending artery, a finding recently chal-
lenged by Hermans et al.41
Postangioplasty variables. Relative gain achieved at
PTCA was both in univariate and multivariate analysis
the strongest predictor (largest F to remove in final
model) of luminal narrowing at follow-up. This variable
probably best reflects the amount of damage inflicted
upon the vessel wall by the angioplasty balloon. It is
conceivable that more damage to the vessel wall with
more deep arterial injury will result in a more aggressive
repair process.1'30-32 Other postangioplasty variables
that were related to more luminal narrowing at fol-
low-up in univariate analysis were higher minimal lu-
men diameter after angioplasty, diameter stenosis after
angioplasty <29.5%, and visible thrombus after angio-
plasty. Thus, a better postangioplasty result leads to
more luminal narrowing or intimal hyperplasia at fol-
low-up. Others have reported that a poorer postangio-
plasty result was predictive of restenosis.1821'23,29,37,42 In
general, they applied the 50% diameter stenosis cut-off
point and, as discussed above, lesions with a poor
postangioplasty result will exceed this cut-off point with
only minimal additional deterioration.
Because lesions with a low percent diameter stenosis
and a large lumen diameter after angioplasty were also
the lesions that underwent a high relative gain at
angioplasty and since this variable was the strongest
independent predictor of the absolute amount of lumi-
nal narrowing at follow-up, percent diameter stenosis
after angioplasty and lumen diameter after angioplasty
were not retained in the multivariate analysis.
Thrombus after angioplasty was retained in the mul-
tivariate model. Five of 16 lesions (31%) with a visible
thrombus after angioplasty were totally occluded at
follow-up and therefore showed a greater overall loss in
lumen diameter.
We did not find an association between coronary
dissection immediately after angioplasty and subse-
quent luminal renarrowing. Conflicting data have been
reported concerning dissection and restenosis.22,23,43-46
However, it is clear that severe dissections are associ-
ated with a higher acute complication45 and restenosis
rate, the latter probably due to a poorer angioplasty
result in combination with the 50% diameter stenosis
criterion.
Procedure-Related Variables
Balloon oversizing (balloon-artery ratio >1.05) was
not related to more luminal narrowing at follow-up.
Some investigators found a positive effect of balloon
oversizing on restenosis29'42 and others have not18'42;
however, in a prospective randomized study, Roubin et
al44 found a higher incidence of acute complications in
case of oversizing but no difference in restenosis rate.
Study Limitations
Although this study suggests several factors that may
be determinants of luminal narrowing after coronary
balloon angioplasty, it does not address the actual
mechanism of restenosis. Vasomotion at follow-up an-
giography cannot be ruled out as a possible cause of the
observed luminal renarrowing in individual lesions,
although intracoronary nitrates in appropriate doses
were administered before each angiography. Mean ref-
erence diameter was not different before PTCA, after
PTCA, and at follow-up (2.64±0.56 mm, 2.70+0.53 mm,
and 2.70±0.56 mm, respectively), suggestive of accurate
control of vasomotion. Because of the relatively small
sample sizes of some variables, P error cannot be ruled
out in this study. Furthermore, in performing multiple
statistical comparisons, there is a risk that some of them
may reach significance by chance alone. The multivari-
ate model was developed and tested in the same popu-
lation. Generally, a model will be less accurate if
assessment of fit is carried out in a different population.
However, the poor fit of the model even when tested in
the same population underscores the poor predictability
of the restenosis process.
The analyses described in this study were based on data
from a restenosis prevention trial (CARPORT). That trial
was designed to investigate whether a certain drug was
capable of reducing the amount of intimal hyperplasia
relative to placebo treatment and not specifically to deter-
mine risk factors for this event. The post hoc nature of the
present analyses might therefore have influenced the
outcome of the analyses. In the CARPORT trial, only
patients with a scheduled angioplasty for a primary lesion
of the native coronary system could be entered. There-
fore, several variables that have been found important in
other analyses such as saphenous vein graft location and
restenosed lesions could not be analyzed. At the time of
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the design of the CARPORT trial, the risk factor ostial
lesion was not known and therefore could not be included
in the analysis.
According to the protocol, patients were to undergo
repeat catheterization within the time window of 6
months±2 weeks. However, if symptoms reappeared
before this predetermined time of follow-up, early an-
giography was performed. If no serious restenosis was
found and/or no reintervention followed and the fol-
low-up period was less than 4 months, the patient was
asked to undergo another angiography 6 months after
the balloon angioplasty. This 4-month cut-off point was
derived from the studies by Nobuyoshi47 and Serruys,s
who showed the time relation of the restenosis process.
In both studies, luminal narrowing continued up to 4
months after balloon dilatation and came to a halt
afterward. In our population, 88 (13.1%) of the lesions
were refilmed before 4 months of follow-up. It might be
possible that these lesions would have further deterio-
rated if catheterization had been performed at 6
months, thereby influencing the analysis. Most of these
patients underwent reintervention (PTCA, bypass
grafting), and a minority refused repeat angiography.
Early repeat angiography is an unavoidable aspect of
this type of studies. It was considered unethical to delay
angiography in patients with symptom recurrence. Min-
imal luminal diameter before angioplasty was 1.04 mm
in both groups; after angioplasty this was 1.67 mm in the
<4-month catheterization group and 1.78 mm in the
6-month catheterization group. At follow-up angiogra-
phy, minimal lumen diameter was 1.06 mm in the <4-
month catheterization group and 1.54 mm in the
6-month catheterization group. Mean loss in lumen
diameter was 0.61 mm with early catheterization and
0.25 mm in the 6-month catheterization group. A mean
lumen diameter of 1.06 mm at follow-up angiography in
the early angiography group represents a recurrence to
the preangioplasty state.
It is well known that developing atherosclerosis is
accompanied by a compensatory enlargement of the
vessel lumen.48 This compensatory enlargement will
camouflage for a long time the true amount of vessel
wall thickening if determined by contrast angiography.
Whether this process of compensatory enlargement
plays a role in the restenosis process after balloon
angioplasty is unknown. It could theoretically have
some repercussions on measurements of change in
lumen diameter when used as a measurement of the
amount of intimal hyperplasia after angioplasty. Tech-
niques that visualize the vessel wall in vivo, like intra-
vascular ultrasound, could give an answer to this
question.
Conclusions
Prediction of luminal narrowing with baseline clinical
and quantitative angiography was shown to be poor.
Only six variables, namely, minimal lumen diameter
before angioplasty, relative gain at angioplasty, lesion
length, diabetes, duration of angina, and thrombus after
angioplasty, were found to be independent determi-
nants of the hyperplastic intimal reaction after balloon
angioplasty. Control of these factors alone, if at all
possible, will not result in a reduction of the amount of
luminal narrowing. Furthermore, since (elective) angio-
plasty is still a procedure performed to alleviate symp-
toms, it does not seem feasible to deny diabetics,
patients with recent onset angina, or patients with a
severe lesion a balloon angioplasty procedure. Resteno-
sis is obviously a process that cannot be predicted by
simple clinical and morphological patient or lesion
characteristics. Therefore, additional biochemical or
histochemical factors49 of importance in the restenosis
process should be investigated and, where possible,
tackled with appropriate pharmacological intervention.
The variable most strongly associated with the
amount of luminal narrowing at follow-up was the
relative gain at angioplasty. It must be noted that
lesions with a large gain at PTCA not only can but also
will undergo a larger loss in lumen diameter at follow-
up. Because drugs currently under development to
prevent the restenosis process after balloon angioplasty
are designed to reduce the absolute amount of intimal
hyperplasia, the highest possible benefit of a new drug
treatment might be expected in lesions with the charac-
teristics retained in the present multivariate model.
Appendix
The following people and institutions form the CARPORT
study group (Coronary Artery Restenosis Prevention On
Repeated Thromboxane Antagonism).
Clinical Centers
Thoraxcenter (Rotterdam, The Netherlands): Patrick W.
Serruys, MD*t; Benno J. Rensing, MD; Hans E. Luijten, MD;
Pim J. de Feyter, MD; Haryanto Suryapranata, MD; Marcel
van den Brand, MD; Jos R.T.C. Roelandt, MD; Klinikum
Charlottenburg (Berlin, Germany): Wolfgang Rutsch, MD*;
Maria Klose, MD; C.H.R.U. de Nancy-Hopitaux de Brabois
(Nancy, France): Nicolas Danchin, MD*; Yves Juilliere, MD;
A. Hueber, MD; Francois Cherrier, MD; Onze Lieve Vrouw
Ziekenhuis (Aalst, Belgium): Guy R. Heyndrickx, MD*; Paul
Nellens, MD; Bernard de Bruyne, MD; Marc Goethals, MD;
Peter Goemare, RN; St Antonius Ziekenhuis (Nieuwegein,
The Netherlands): E. Gijs Mast, MD*; Fokke A.M. Jonkman,
MD; R. Melvin Tjon Joe Gin, MD; U.C.L. St Luc University
Hospital (Brussels, Belgium): William Wijns, MD*; M. Delg-
adillo; Jean Renkin, MD.
Quantitative Angiographic Core Lab
Cardialysis/Thoraxcenter (Rotterdam, The Netherlands):
Patrick W. Serruys, MD; Benno J. Rensing, MD; Walter R.M.
Hermans, MD; Jaap Pameijer.
Data Coordinating Center
Socar SA (Givrins, Switzerland): Jeroen Vos, MD; Mari-
anne Bokslag; Jacobus Lubsen, MD.
Glaxo Group Research Ltd
Greenford, Middlesex, England: Anthony McAllister, PhD;
Michael Perelman, MD.
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